Leading off of the Phase 2 CTP-543 trials, Chief Development Officer of Concert Pharmaceuticals, Dr. James V. Cassella states: “The planned initiation of the Phase 3 program, combined with the positive results of the Phase 2 dose ranging trial, show the continued momentum for our development of CTP-543 for patients with alopecia areata,”
The intent is to begin Phase 3 late this year, but is dependent on the circumstances surrounding COVID-19. The trials will be taking place in Canada, US and Europe and will expect to involve about 700 patients with moderate-to-severe alopecia areata.
Click here to view the full press release.
For more information about Concert Pharmaceuticals and their clinical trials, please visit https://www.concertpharma.com/product-pipeline/ctp-543/
